TITLE: Oxidative Stress, DNA Repair and Prostate Cancer Risk. PRINCIPAL INVESTIGATOR: Hua Zhao, Ph.D.

Similar documents
TITLE: Oxidative Stress, DNA Repair and Prostate Cancer Risk. PRINCIPAL INVESTIGATOR: Hua Zhao, Ph.D.

CONTRACTING ORGANIZATION: University of California Lawrence Berkeley National Laboratory Berkeley, CA 94720

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

TITLE: Dietary Genistein and Prostate Cancer Chemoprevention

CONTRACTING ORGANIZATION: North Eastern Ohio Universities Rootstown OH 44202

TITLE: Neural Protein Synuclein (SNCG) in Breast Cancer Progression

TITLE: New Advanced Technology to Improve Prediction and Prevention of Type 1 Diabetes

Fort Detrick, Maryland

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

TITLE: Evaluation of DNA Methylation as a Target for Intraductal Therapy for Ductal Carcinoma in Situ of the Breast

TITLE: Genes Associated with Food Allergy and Eosinophilic Esophagitis

CONTRACTING ORGANIZATION: Western Institute For Biomedical Research Salt Lake City, UT

CONTRACTING ORGANIZATION: Sloan-Kettering Institute for Cancer Research New York, NY 10021

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

Award Number: W81XWH TITLE: Global Positioning Systems (GPS) Technology to Study Vector-Pathogen-Host Interactions

CONTRACTING ORGANIZATION: Oregon Health & Science University Portland OR 97239

Award Number: W81XWH

TITLE: Enhancing the Anti-Tumor Activity of ErbB Blockers with Histone Deaccetylase (HDAC) Inhibition in Prostate Cancer Cell Lines

AD (Leave blank) Award Number: W81XWH TITLE: Targeting Autophagy for the Treatment of TSC and LAM. PRINCIPAL INVESTIGATOR: Elizabeth Henske

U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

CONTRACTING ORGANIZATION: Johns Hopkins Bloomberg School of Public Health

TITLE: Estrogen-DNA Adducts as Novel Biomarkers for Ovarian Cancer Risk and for Use in Prevention

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

Award Number: W81XWH

Approved for public release; distribution unlimited

TITLE: Role of ADAM15 in Tumor/Endothelial Interactions Prostate Cancer Regression

TITLE: Inhibitors of Histone Deacetylases for Radiosensitization of Prostate Cancer

TITLE: Short-Term Exercise and Prostate Cancer Prevention in African American Men. CONTRACTING ORGANIZATION: Howard University Washington DC 20059

TITLE: Adipose Estrogen and Increased Breast Cancer Risk in Obesity: Regulation by Leptin and Insulin

TITLE: Long Term Outcomes of BRCA1/BRCA2 Mutation Testing. CONTRACTING ORGANIZATION: Georgetown University Washington, DC

CONTRACTING ORGANIZATION: University of Minnesota St Paul, MN 55108

U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

AD (Leave blank) TITLE: Proteomic analyses of nipple fluid for early detection of breast cancer

TITLE: 64Cu-DOTA-trastuzumab PET imaging in women with HER2 overexpressing breast cancer

Detection of Prostate Cancer Progression by Serum DNA Integrity

TITLE: Prostate Expression Databases: Gene Expression Resources for Comparative Studies of Prostate Carcinogenesis

TITLE: Effect of Reminder Telephone Calls on Mammography Compliance in High Risk

AWARD NUMBER: W81XWH TITLE: Androgen Deprivation Therapy and Cognitive Impairment. PRINCIPAL INVESTIGATOR: Robert N. Pechnick, Ph.D.

TITLE: MicroRNA in Prostate Cancer Racial Disparities and Aggressiveness

AWARD NUMBER: W81XWH TITLE: Gulf War Illness as a Brain Autoimmune Disorder. PRINCIPAL INVESTIGATOR: Apostolos Georgopoulos, MD, PhD

CONTRACTING ORGANIZATION: Regents of the University of Michigan Ann Arbor, MI 48109

AWARD NUMBER: W81XWH TITLE: Treatment of Pain and Autonomic Dysreflexia in Spinal Cord Injury with Deep Brain Stimulation

CONTRACTING ORGANIZATION: Mount Sinai School of Medicine New York, New York

TITLE: Prazosin for Treatment of Patients With PTSD and Comorbid Alcohol Dependence

Award Number: W81XWH TITLE: Dietary Fish Oil in Reducing Bone Metastasis of Breast Cancer

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

TITLE: Properties of Leukemia Stem Cells in a Novel Model of CML Progression to Lymphoid Blast Crisis

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

Expression and Promoter Methylation of P16INK4A During Estrogen-Induced Mammary Carcinogenesis in the ACI Rat. Omaha, NE

TITLE: Targeting the Immune System s Natural Response to Cell Death to Improve Therapeutic Response in Breast Cancers

TITLE: Interchromosomal Associations that Alter NF1 Gene Expression Can Modify Clinical Manifestations of Neurofibromatosis 1. Palo Alto, CA 94304

TITLE: Identification of New Serum Biomarkers for Early Breast Cancer Diagnosis and Prognosis Using Lipid Microarrays.

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

CONTRACTING ORGANIZATION: Cleveland Clinic Foundation Cleveland, OH 44195

TITLE: Gulf War Illness Evaluation of an innovative detoxification program

CONTRACTING ORGANIZATION: Cold Spring Harbor Laboratory Cold Spring Harbor, NY 11724

TITLE: A Tissue Engineering Approach to Study the Progression of Breast Tumor Metastasis in Bone

TITLE: Selective Oncolytic Therapy for Hypoxic Breast Cancer Cells. CONTRACTING ORGANIZATION: Ordway Research Institute Albany, New York 12208

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

TITLE: Investigating the Role of TBX2 in the Inhibition of Senescence in Prostate Cancer

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

TITLE: A PSCA Promoter Based Avian Retroviral Transgene Model of Normal and Malignant Prostate

CONTRACTING ORGANIZATION: Vanderbilt University Medical Center Nashville, TN

Page 1 AWARD NUMBER: W81XWH TITLE: A Novel Pleiotropic Anti-Inflammatory Drug to Reduce ARDS Incidence. PRINCIPAL INVESTIGATOR: Gary Nieman

Award Number: W81XWH TITLE: CYP1B1 Polymorphism as a Risk Factor for Race-Related Prostate Cancer

CONTRACTING ORGANIZATION: Fred Hutchinson Cancer Research Center Seattle, WA 98109

TITLE: The Role of HOX Proteins in Androgen-Independent Prostate Cancer

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

Award Number: W81XWH TITLE: "Longitudinal Study of a Novel Performance-based Measure of Daily Function."

Sphingosine-1-Phosphate Receptor Subtype 3: A Novel Therapeutic Target of K-Ras Mutant Driven Non-Small Cell Lung Carcinoma

CONTRACTING ORGANIZATION: UNIVERSITY OF ILLINOIS Chicago, IL 60612

RECIPIENT: Lankenau Institute for Medical Research, Wynnewood, PA 19096

TITLE: The Role Of Alternative Splicing In Breast Cancer Progression

Approved for public release; distribution unlimited

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

TITLE: Maximizing Energy After Traumatic Brain Injury: A Novel Intervention

CONTRACTING ORGANIZATION: Veterans Medical Research Foundation San Diego, CA

La Jolla, CA Approved for Public Release; Distribution Unlimited

TITLE: Homeostatic and Circadian Abnormalities in Sleep and Arousal in Gulf War Syndrome

TITLE: Computerized Tailored Interventions for Behavioral Sequelae of Post-Traumatic Stress Disorder in Veterans

TITLE: Targeted Eradication of Prostate Cancer Mediated by Engineered Mesenchymal Stem Cells

CONTRACTING ORGANIZATION: University of Texas M.D. Anderson Cancer Center Houston, TX 77030

TITLE: The Role of hcdc4 as a Tumor Suppressor Gene in Genomic Instability Underlying Prostate Cancer

AD (Leave blank) TITLE: Trial of Naltrexone and Dextromethorphan for Gulf War Veterans Illnesses

Award Number: W81XWH TITLE: Characterizing an EMT Signature in Breast Cancer. PRINCIPAL INVESTIGATOR: Melanie C.

TITLE: Effect of COX-2 (PGE2) and IL-6 on Prostate Cancer Bone Mets

TITLE: Harnessing GPR17 Biology for Treating Demyelinating Disease

TITLE: Proteomic Mapping of the Immune Response to Gluten in Children with Autism

TITLE: Investigation of the Akt/PKB Kinase in the Development of Hormone-Independent Prostate Cancer

TITLE: Development of Antigen Presenting Cells for adoptive immunotherapy in prostate cancer

TITLE: Post-Traumatic Headache and Psychological Health: Mindfulness Training for Mild Traumatic Brain Injury

TITLE: Responsiveness of a Neuromuscular Recovery Scale for Spinal Cord Injury: Inpatient and Outpatient Rehabilitation

Award Number: W81XWH TITLE: A Novel Membrane-Permeable, Breast-Targeting, Pro-Apoptotic Peptide for Treatment of Breast Cancer

TITLE: Effects of Tobacco Smoke (TS) on growth of clear cell renal cell carcinoma (ccrcc)

TITLE: Uncarboxylated Osteocalcin and Gprc6a Axis Produce Intratumoral Androgens in Castration- Resistant Prostate Cancer

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

TITLE: HER2/neu Antisense Therapeutics in Human Breast Cancer. CONTRACTING ORGANIZATION: Washington University School of Medicine St.

TITLE: A Phase II Trial of Androgen Suppression and Radiation Therapy with Samarium-1 53 in Localized, High-Risk, Prostate Cancer

CONTRACTING ORGANIZATION: Southern Illinois University School of Medicine, Springfield, IL

Transcription:

AD Award Number: W81XWH-08-1-0416 TITLE: Oxidative Stress, DNA Repair and Prostate Cancer Risk PRINCIPAL INVESTIGATOR: Hua Zhao, Ph.D. CONTRACTING ORGANIZATION: Health Research Inc Buffalo, NY 14263 REPORT DATE: August 2009 TYPE OF REPORT: Annual report PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012 DISTRIBUTION STATEMENT: Approved for public release; distribution unlimited The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE Form Approved OMB No. 0704-0188 Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS. 1. REPORT DATE (DD-MM-YYYY) 2. REPORT TYPE 01-08-2009 Annual report 3. DATES COVERED (From - To) 1 AUG 2008-31 JUL 2009 4. TITLE AND SUBTITLE 5a. CONTRACT NUMBER Oxidative stress, DNA repair and prostate cancer risk 5b. GRANT NUMBER W81XWH-08-1-0416 5c. PROGRAM ELEMENT NUMBER 6. AUTHOR(S) 5d. PROJECT NUMBER Hua Zhao, Ph.D. Email: hua.zhao@roswellpark.org 5e. TASK NUMBER 5f. WORK UNIT NUMBER 7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) 8. PERFORMING ORGANIZATION REPORT NUMBER Health Research Inc Buffalo, NY 14263 9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) 10. SPONSOR/MONITOR S ACRONYM(S) U.S. Army Medical Research And d Material Command Fort Detrick, Maryland, 21702-5012 NUMBER(S) 11. SPONSOR/MONITOR S REPORT 12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for public release; distribution unlimited 13. SUPPLEMENTARY NOTES 14. ABSTRACT Oxidative stress, which results from an imbalance between ROS and antioxidant capacities, can cause a wi de range of direct or indirect DNA damage. There are extensive DNA repair systems that can correct DNA damage caused by ROS before cell replication and mutation fixation. Although oxidative stress app ears to be important in the etiology of prostate cancer, so far there is no study to com prehensively investigate the association between DRC of oxidative DNA damage as a phenotype and prostate cancer risk. W e hypothesize that DRC of oxidative DNA da mage as a phenotype m ay modify prostate cancer risk. S o far, the study has recrui ted 156 cases and 132 controls. The proposed molecular analysis has begun for all three specific aims. 15. SUBJECT TERMS microrna ovarian cancer 16. SECURITY CLASSIFICATION OF: 17. LIMITATION OF ABSTRACT a. REPORT U b. ABSTRACT UU c. THIS PAGE U UU 18. NUMBER OF PAGES 19a. NAME OF RESPONSIBLE PERSON 19b. TELEPHONE NUMBER (include area code) Standard Form 298 (Re. 8-98) v Prescribed by ANSI Std. Z39.18

Table of Contents Page Introduction..... 4 Body.. 4 Key Research Accomplishments... 5 Reportable Outcomes 5 Conclusion 5

Introduction Many of the known and suspected risk factors for prostate cancer are associated with elevated levels of ROS (advancing age, inflammation, androgen, high-fat diet), or decreased antioxidant capabi lities (fruit and vegetable consumption, specific dietary antioxidants, such as selenium, vitam in E and caroteno ids). Oxidativ e stress, which results from an im balance between ROS and antioxidant capacities, can cause a wide range of direct or indirect DNA da mage. There are extensive DNA repair system s that can correct DNA da mage caused by ROS befo re cell replication and mutation fixation. For instance, ROS-caused base dam ages and single strand breaks are m ainly repaired by BER and NER; DNA a dducts caused by ROS-indu ced lipid peroxidation are repaired by NER; and ROS caused-dna dou ble strand br eaks are repaired by HRR and NHEJ. However, DRC is substantially variable am ong individuals in the population, and suboptimal DRC of oxidative DNA da mage might increase genom ic instability and hence, increase risk of cancer. Although oxidati ve stress appears to be im portant in the etiology of prostate cancer, so far there is no study to com prehensively investigate the association between DRC of oxidative DNA da mage as a phenotype and prostate cancer risk. Body Study subject recruitment: At the end of September of 2009, we have recruited 156 m en diagnosed with prostate cancer as cases and 132 healthy men as controls. Both cases and controls were recruited through DataBank BioRepository (BDDR) of Roswell Park Cancer Institute (RPCI). On average, we have around 15 cases and 15 controls per month. We don t expect any significant delay to recruit 300 cases and 300 controls. Specific aim 1: we will m easure levels of 8-OH-dG after exposure to H 2 O 2 in PBLs in 300 m en wi th prostate cancer and 300 health y controls, using ELISA based m utagen sensitivity assay. Our hypothesis is that cases will exhibit higher levels of 8-OH-dG after exposure to H 2 O 2 (reflecting lower BER activity) compared with healthy controls. So far, the proposed 8-OH-dG analysis has been carrie d out in 98 prostate cancer cases and 87 healthy controls. The mean levels of 8-OH-dG were significantly h igher in cases th an in controls (4.52 vs. 3.11, P<0.01). In further stra tified analysis, using median levels of 8- OH-dG in controls as the cutoff point, we found higher levels of 8-OH-dG was associated with 1.45-fold increased prostate cancer risk (OR= 1.45, 95% CI: 1.04 to 2.35). Specific aim 2: we will assess lev els of DRC of DNA a dducts indu ced by 4-HNE in PBLs in 300 prostate cancer cases and 300 healthy controls, using plasm id based modified HCR assay. 4-HNE is a m ajor pr oduct of endogenous li pid peroxidation. 4- HNE caused DNA adducts is m ainly repaired by NER. Our hypothesis is that cases will exhibit lower levels of NER of 4- HNE caused DNA add ucts com pared with healthy controls. So far, the proposed 4-HNE based host cell reactivation (HCR) assay has been carried out in 75 prostate cancer cas es and 77 healthy controls. The m ean levels of 4- HNE based HCR were m arginally lower in cases than in controls (6.7% vs. 8.6%, P=0.052). In further stratified analysis, using m edian levels of 4-HNE based in controls 4

as the cutoff point, we found lower levels of 4-HNE based was not associated with the prostate cancer risk (OR= 1.21, 95% CI: 0.75 to 1.89). Because of the small sample size, we have to be very cautious to interpret the results. Specific aim 3: we will assess levels of HHR and NHEJ of double strand breaks in PBLs in 300 men with prostate cancer and 300 health y controls, using plasm id based modified HCR assays. Our hypothesis is th at cases w ill exhibit lower levels of HR and NHEJ compared with healthy controls. For HR a ssay, the assay has been carried ou t in 5 4 prostate cancer cases and 47 healthy controls. The mean levels of HR activity were lower in cases than in controls (10.5% vs. 12.4%, P=0.34), but the difference didn t reach statistically significan t. For NHEJ assay, the as say has been carried out in 54 prostate cancer cases and 47 healthy controls. The mean levels of HR activity were lower in cases than in con trols (7.9% vs. 8.9, P=0.44), but the difference didn t reach statistically significant. Overall, we expect to com plete the proposed analyses on tim e. No m ajor delay is forecasted. Key Research Accomplishments 1. At the end of September of 2009, we have recruited 156 men diagnosed with prostate cancer as cases and 132 healthy men as controls. We don t expect any delay in the study subject recruitment. 2. The proposed molecular analyses in specific aims 1-3 have run well. We expect to complete the proposed analyses on time. 3. We have obtained questionnaire data from 156 patients and 132 controls. 4. In training, Dr. Mohler (the mentor) has regularly consulted the project. Dr. Zhao has also involved in Dr. Mohler s other research project. Reportable outcomes Because the study is s till ongo ing, at this point, we don t have any m anuscript in preparation. But, we expect to begin to prepare two manuscripts pretty soon. Conclusion The study has run smoothly so far. We don t expect any delay. 5